
Best practice in biologically-based modelling for Risk Assessment

Contributed by George Loizou
Friday, 27 March 2009
Last Updated Friday, 03 April 2009

Eurotox 2009 - Dresden, Germany

Symposium 6 (WHO/International Programme on Chemical Safety) Tuesday, September 15

The increasing use of pharmacokinetic models in chemical risk assessments is recognised. It is necessary to develop a common understanding of what constituents are required to develop an internationally acceptable model and how to validate it. A common understanding would facilitate sharing of models and model evaluations as well as consistent application in risk assessments. Consideration will be given to:

- 1) Model development,
- 2) Model characterization, i.e. methods to describe how consistent the model is with biology; strengths and limitations of available model and data, such as sensitivity analyses,
- 3) Model documentation,
- 4) Model evaluation, i.e. independent review.

Presentations by

Dr. Bette Meek, Canada, Prof. Dr. Ursula Gundert-Remy, Germany, Dr. George Loizou, UK, Dr. Harvey J. Clewell III, USA, Dr. Olavi Pelkonen, Finland